EOGT_A130022J15Rik Inhibitors
Chemical inhibitors of EOGT_A130022J15Rik can exert their inhibitory effects by interfering with the protein glycosylation process, which is essential for the proper function of EOGT_A130022J15Rik. Tunicamycin disrupts N-linked glycosylation by inhibiting the transfer of N-acetylglucosamine to dolichol phosphate, an essential step for the glycosylation process that EOGT_A130022J15Rik relies on. Swainsonine and kifunensine target mannosidase II and mannosidase I, respectively, leading to the accumulation of misfolded glycoproteins and disrupting the glycosylation processes necessary for EOGT_A130022J15Rik to modify its substrates. Castanospermine and 1-Deoxynojirimycin both inhibit glucosidases, which are responsible for trimming glucose residues, a vital step for subsequent glycosylation processes. By inhibiting these enzymes, these chemicals prevent the proper processing of glycoproteins, which are substrates for EOGT_A130022J15Rik, thus impeding its activity.
Additionally, chemicals such as brefeldin A and monensin disrupt the structure and function of the Golgi apparatus as well as Golgi ion gradients, respectively. Since EOGT_A130022J15Rik is localized and active in the Golgi, this disorganization inhibits the protein's ability to access glycosylation machinery and substrates. Decylubiquinone, by disrupting electron transport, creates an environment that indirectly affects EOGT_A130022J15Rik's activity by not being conducive to proper folding and modification of proteins. Cycloheximide, while not a direct inhibitor, reduces the availability of nascent glycoproteins for EOGT_A130022J15Rik to modify by inhibiting protein synthesis at the ribosomal level. Deoxymannojirimycin, another mannosidase inhibitor, results in improper glycoprotein assembly, which in turn affects the substrate availability for EOGT_A130022J15Rik. Lastly, nocodazole and colchicine each disrupt microtubule polymerization, which is crucial for the intracellular transport and proper localization of proteins. This disruption interferes with the trafficking of glycosylation enzymes and substrates necessary for the activity of EOGT_A130022J15Rik.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin blocks N-linked glycosylation by inhibiting the transfer of N-acetylglucosamine to dolichol phosphate, an early step in the glycosylation process. EOGT_A130022J15Rik requires glycosylated substrates; inhibition here would prevent its function. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits mannosidase II, leading to the accumulation of misfolded glycoproteins. This would disrupt the glycosylation processes necessary for EOGT_A130022J15Rik to properly modify its substrates. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine inhibits mannosidase I in the glycosylation pathway, which could result in improperly glycosylated proteins that EOGT_A130022J15Rik could not effectively modify, thereby inhibiting its functional activity. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine inhibits glucosidases I and II. Inhibition of these enzymes prevents the proper trimming of glucose residues, vital for subsequent glycosylation steps, potentially disrupting EOGT_A130022J15Rik's enzymatic activity. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
As an inhibitor of glucosidase I, 1-Deoxynojirimycin leads to an accumulation of glycoproteins with incorrect glycosylation patterns, which could inhibit the function of EOGT_A130022J15Rik by depriving it of properly glycosylated substrates. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi apparatus, where EOGT_A130022J15Rik is localized and active. This disruption can inhibit the protein's ability to access glycosylation machinery and substrates. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin acts by disrupting Golgi ion gradients, which can interfere with glycosylation processing and trafficking, potentially inhibiting the function of EOGT_A130022J15Rik by impairing the glycosylation of its substrates. | ||||||
Decylubiquinone | 55486-00-5 | sc-358659 sc-358659A | 10 mg 50 mg | $70.00 $269.00 | 10 | |
Decylubiquinone, a ubiquinone analog, disrupts electron transport and can create a cellular environment that is not conducive to proper folding and modification of proteins, indirectly affecting EOGT_A130022J15Rik's activity. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits protein synthesis at the ribosome level. Although not a direct inhibitor of EOGT_A130022J15Rik, it would lead to a reduction in the availability of nascent glycoproteins for EOGT_A130022J15Rik to modify. | ||||||
Deoxymannojirimycin hydrochloride | 84444-90-6 | sc-201360 sc-201360A | 1 mg 5 mg | $93.00 $239.00 | 2 | |
Deoxymannojirimycin inhibits mannosidase, an enzyme involved in glycoprotein processing. This could result in improper glycoprotein assembly, indirectly inhibiting the substrate availability for EOGT_A130022J15Rik. | ||||||